Skip to content
Back
  • Home
  • About us
    • Company focus
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
    • R&D Focus
    • R&D Levers
  • Pipeline
    • Pipeline
    • JM-010
    • CP-012
    • Discovery
  • News
    • Press releases
    • Upcoming events
  • Contact
    • Business Development
    • Social network

JM-010

Learn about JM-010

About JM-010

Parkinson’s disease is a common neurological disorder caused by the progressive degeneration of neurons producing dopamine. Standard of care in Parkinson’s disease is treatment with dopamine replacement therapies such as Levodopa or dopamine agonists. However, in advanced stages of Parkinson’s disease, patients treated with dopamine replacement therapies often suffer from dyskinesia, a condition that strongly impacts quality of life and in severe cases can be life-threatening. By applying the basic principles fundamental to our PRECISION MEDICINE methodology, JM-010 was developed as an innovative approach to accelerate the development of new treatment options for Parkinson’s disease patients suffering from dyskinesia.

JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson’s disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Ph1 clinical safety and Ph2 clinical proof of concept studies. Currently, JM-010 is undergoing Ph2 clinical studies in Europe and US.

Recent News

September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

South Korea map icon

Contera Pharma Korea

7, SangDo-Ro, Dongjak-Gu
Seoul, 06955
Korea

info@conterapharma.com

Contact us

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

Contera Pharma Korea

7, SangDo-Ro,

Dongjak-Gu

Seoul, 06955

Korea

info@conterapharma.com

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy

Bukwang

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.

Discover Bukwang

Designet af Standoutmedia